Reported 10 days ago
BTIG analyst Julian Harrison has maintained a Buy rating on Apogee Therapeutics Inc. (NASDAQ:APGE) with a price target of $115. The positive outlook is attributed to the company's promising clinical developments, particularly its drug APG777 which shows potential in treating asthma and other conditions. Ongoing trials and data updates are expected to confirm APG777's safety and efficacy, reinforcing the Buy recommendation.
Source: YAHOO